Advertisement

EDAP

Edap Tms S.a.

Healthcare · USD

Set alert

Price alert · EDAP

All alert types
4.76 USD 0.00 0.00%
As of Jun 2, 2026 Extended hours 4.53 -4.77%
Bid
4.31 × 1
Ask
4.35 × 1
4.50 Day range 4.80
2.14 52-week range 8.50
YTD
+44.53%
1 year
+168.64%
Open
4.75
Prev close
4.76
Mkt cap
82.37M
Vol
28.86K
Avg vol
161.81K
EPS
-0.62
P/E
0.00
Div yield
0.00%
More statistics
Low
4.50
High
4.80
Forward P/E
-4.72
Beta
0.38
Short ratio
0.22
Inst. own
42.45%
Dividend
0.00
Ex-div date
50-d avg
2.53
200-d avg
4.66
1y target
10.67

3M chart

Chart tools
Interval
EDAP three-month price chart3.103.533.964.384.81Mar 2Mar 19Apr 7Apr 24May 12Jun 1

Key statistics

Market cap
82.37M
Enterprise value
64.67M
Trailing P/E
0.00
Forward P/E
-4.72
PEG ratio
0.00
Price / sales
1.30
Price / book
1.94
EPS (TTM)
-0.62
Beta
0.38
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-34.88%
Revenue (TTM)
63.41M
Revenue growth
11.60%
Free cash flow
-6.42M
Total cash
25.48M
Total debt
8.61M
Return on equity
-43.07%
Shares outstanding
37.10M
Short % of float
0.15%
50-day average
2.53
200-day average
4.66

Analyst view

Consensus: none

Price target (mean) 10.67 +124.3% upside
Target (low)
5.00
Target (mean)
10.67
Target (high)
19.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate -0.1095.

Earnings history

Financials — quick view

All financials
EDAP Revenue — quarterly 17.81M
2022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 2026
EDAP Net income — quarterly -9.08M
2022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 2026
EDAP EPS — quarterly -0.24
2022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 2026

Earnings

EDAP recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.16-0.19-0.03-18.75%
Aug 28, 2024Jun 1, 2024-0.14-0.18-0.04-28.57%
May 16, 2024Mar 1, 2024-0.10-0.13-0.03-30.00%
Mar 27, 2024Dec 1, 2023-0.02-0.15-0.13-650.00%
Nov 9, 2023Sep 1, 2023-0.11-0.12-0.01-9.09%
Aug 24, 2023Jun 1, 2023-0.03-0.14-0.11-366.67%

Upgrades / downgrades

EDAP analyst upgrades and downgrades
DateFirmActionFromTo
Aug 29, 2024HC Wainwright & Co.reitBuyBuy
Jul 22, 2024HC Wainwright & Co.reitBuyBuy
May 17, 2024HC Wainwright & Co.reitBuyBuy
Apr 1, 2024HC Wainwright & Co.mainBuyBuy
Nov 10, 2023Piper SandlermainOverweightOverweight
Aug 25, 2023HC Wainwright & Co.reitBuyBuy

About Edap Tms S.a.

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves hospitals, urology clinics, and research institutions. EDAP TMS S.A. was incorporated in 1979 and is based in Lyon, France.

Sector
Healthcare
Industry
Medical Distribution
Country
France
Website
edap-tms.com

News

Your note

Sign in to keep a note on EDAP — it syncs with the Stock Master app.

Institution ownership

EDAP institution ownership
Holder% heldSharesValueReported
Soleus Capital Management, L.P.19.70%7,309,25416.23MSep 29, 2024
Morgan Stanley9.08%3,369,7707.48MSep 29, 2024
Rock Springs Capital Management, LP4.23%1,568,0003.48MSep 29, 2024
Archon Capital Management LLC2.86%1,060,8812.36MSep 29, 2024
Bruce & Co, Inc.1.49%553,6521.23MSep 29, 2024
Apis Capital Advisors, LLC1.46%540,0001.20MSep 29, 2024

Fund ownership

EDAP fund ownership
Holder% heldSharesValueReported
Bruce & Co., Inc.1.43%529,7941.18MSep 29, 2024
Federated Hermes Kaufmann Fund1.06%395,002876.90KJul 30, 2024
Federated Hermes Kaufmann Small Cap Fund1.06%395,002876.90KJul 30, 2024
Trust for Professional Managers-ActivePassive International Equity ETF0.07%26,64659.15KAug 30, 2024
Fidelity NASDAQ Composite Index Fund0.06%22,76450.54KOct 30, 2024
Federated Hermes Kaufmann Fund II0.01%4,1259.16KSep 29, 2024
Advertisement